HSCS
What one share of HeartSciences holds
Finance Services
We are a healthcare information technology company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”). Our first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems.
HeartSciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Sales | $0.00 |
|---|---|
| Profit | −$3.19 |
| Cash and investments | $0.01 |
| Debt | $0.95 |
| Book value | −$0.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.43 | −$145.48 | $0.06 | −$109.86 | — | −$182.19 |
| 2023 | $0.06 | −$79.92 | $0.23 | −$72.85 | — | $2.28 |
| 2024 | $0.05 | −$18.74 | $0.18 | −$17.40 | — | $10.81 |
| 2025 | $0.00 | −$9.34 | $0.00 | −$7.90 | $0.00 | $0.18 |
| 2026 | $0.00 | −$3.48 | $0.00 | −$2.83 | $0.00 | $0.07 |